Market News
Latest news from Stock markets.
Vaalco Energy: Cash Flow Update
Vaalco Energy expects FPSO repairs to conclude by January 31. Drilling rig delays in Gabon push up to $100 million in expenses into 2026. Successful sulfur removal from high-sulfur wells has lifted total production above projections.
...keep reeding on seekingalpha.com
UIVM: Unconvincing Blend Of Value And Momentum
VictoryShares International Value Momentum ETF blends value and momentum factors with a low-volatility weighting. UIVM is well-diversified in countries and holdings, with a focus on financials. UIVM's performance lags FDT and several international value/momentum peers.
...keep reeding on seekingalpha.com
ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
The Cut Countdown
U.S. equity markets climbed to the cusp of fresh record-highs as another soft slate of employment data and modest PCE inflation data helped solidify the case for another rate cut. ADP provided the most evident signs of cooling labor markets, posting job losses in three of the past six months and a cooldown in wage growth to four-year lows. The PCE report showed corresponding disinflation in discretionary services categories, offsetting modest upward pressures on goods prices, resulting in the first monthly deceleration in core inflation since April.
...keep reeding on seekingalpha.com
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
NEW YORK , Dec. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. So what: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on prnewswire.com
PRMB DEADLINE: Faruqi & Faruqi Reminds Primo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 - PRMB
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Primo Brands to Contact Him Directly to Discuss Their Options If you purchased or acquired securities: (a) the common stock of Primo Water between June 17, 2024 through November 8, 2024, inclusive, and/or (b) the common stock of Primo Brands between November 11, 2024 through November 6, 2025, inclusive (collectively, the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Primo Brands Corporation ("Primo Brands" or the "Company") (NYSE: PRMB) and reminds investors of the January 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
DEFT UPCOMING DEADLINE: Faruqi & Faruqi Reminds In DeFi Technologies Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 30, 2026 - DEFT
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in DeFi Technologies to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in DeFi Technologies between May 12, 2025 and November 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DeFi Technologies Inc. ("DeFi Technologies" or the "Company") (NASDAQ: DEFT) and reminds investors of the January 30, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
FLY DEADLINE: Faruqi & Faruqi Reminds Firefly Aerospace Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 - FLY
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Firefly Aerospace to Contact Him Directly to Discuss Their Options If you purchased or otherwise acquired: (a) Firefly common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about August 7, 2025 (the "IPO" or "Offering"); and/or (b) Firefly securities between August 7, 2025 and September 29, 2025, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Firefly Aerospace Inc. ("Firefly" or the "Company") (NASDAQ: FLY) and reminds investors of the January 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
STUB DEADLINE: Faruqi & Faruqi Reminds StubHub Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 23, 2026 - STUB
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in StubHub to Contact Him Directly to Discuss Their Options If you purchased or otherwise acquired stock of StubHub pursuant and/or traceable to StubHub's registration statement for the initial public offering held on or about September 17, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against StubHub Holdings, Inc. ("StubHub" or the "Company") (NYSE: STUB) and reminds investors of the January 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
VICI Properties: The Drop I Anticipated Arrived (Rating Upgrade)
VICI's 33% share price decline has reset valuation to levels that finally reflect realistic risk—creating a more attractive long-term entry point. Management's capital discipline and long lease maturities underpin my upgraded rating, as fundamentals remain far stronger than the recent drawdown suggests. At today's price, long-term investors can reasonably expect double-digit total returns, with a potential +30% share price appreciation, should VICI revert toward its historical valuation.
...keep reeding on seekingalpha.com
The Market Is Giving Investors an Unbeatable Opportunity to Buy This Long-Term Artificial Intelligence (AI) Winner (Hint: Not Palantir or Nvidia)
Nvidia and Palantir provide key components for building and getting the most out of new AI models. But Meta Platforms has some of the best use cases for AI, and it's already showing up in revenue growth.
...keep reeding on fool.com
INSP DEADLINE: Faruqi & Faruqi Reminds Inspire Medical Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 5, 2026 - INSP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Inspire Medical to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Inspire Medical between August 6, 2024 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inspire Medical Systems, Inc. ("Inspire Medical" or the "Company") (NYSE: INSP) and reminds investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
KMX DEADLINE: Faruqi & Faruqi Reminds Baxter International Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2026 - KMX
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In CarMax To Contact Him Directly To Discuss Their Options If you suffered losses in CarMax between June 20, 2025 and September 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CarMax, Inc. ("CarMax" or the "Company") (NYSE: KMX) and reminds investors of the January 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
WPP DEADLINE: Faruqi & Faruqi Reminds WPP Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - WPP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In WPP To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in WPP between February 27, 2025 and July 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against WPP plc ("WPP" or the "Company") (NYSE: WPP) and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
GitLab Shares Plunge. Why It May Be Time to Load Up on the Stock Ahead of the New Year.
GitLab shares plunged on conservative guidance ahead of a new CFO taking over. The company reported strong revenue growth and vastly improved operating margins.
...keep reeding on fool.com
Victoria's Secret: The Brand Is Regaining Momentum
Victoria's Secret reported great strength in Q3 as same-store sales improved by 8%, driving year-on-year earnings gains. The brand is clearly reinvigorating after a successful October fashion show. High debt and thin margins make a turnaround continuation critical for VSCO.
...keep reeding on seekingalpha.com
FCX DEADLINE: Faruqi & Faruqi Reminds Freeport-McMoran Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 - FCX
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Freeport-McMoran To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Freeport between February 15, 2022 and September 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Freeport-McMoran Inc. ("Freeport" or the "Company") (NYSE: FCX) and reminds investors of the January 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
MRX DEADLINE: Faruqi & Faruqi Reminds Marex Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - MRX
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Marex to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Marex between May 16, 2024 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marex Group plc ("Marex" or the "Company") (NASDAQ: MRX) and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Tvardi to Contact Him Directly to Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ: TVRD).
...keep reeding on newsfilecorp.com
NJDCY INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nidec
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Nidec to Contact Him Directly to Discuss Their Options If you suffered significant losses in Nidec stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nidec Corporation ("Nidec" or the "Company") (OTC: NJDCY).
...keep reeding on newsfilecorp.com
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Telecom giant Verizon has the highest yield in the Dow at 6.8%. Energy Goliath Chevron currently offers a hefty 4.6% yield.
...keep reeding on fool.com
TLX DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - TLX
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Telix to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX) and reminds investors of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel
Capricor Therapeutics maintains a "Hold" rating despite positive phase 3 HOPE-3 results for Deramiocel in DMD cardiomyopathy. HOPE-3 met both primary [PUL v2.0] and key secondary [LVEF] endpoints, aligning with FDA's requirements for potential BLA resubmission of Deramiocel. Regulatory uncertainty remains, particularly regarding CMC issues and whether or not HOPE-3 fully satisfies FDA approval criteria.
...keep reeding on seekingalpha.com
BTDR DEADLINE: Faruqi & Faruqi Reminds Bitdeer Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 2, 2026 - BTDR
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Bitdeer to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Bitdeer between June 6, 2024 and November 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bitdeer Technologies Group ("Bitdeer" or the "Company") (NASDAQ: BTDR) and reminds investors of the February 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
JHX DEADLINE: Faruqi & Faruqi Reminds James Hardie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 23, 2025 - JHX
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In James Hardie To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in James Hardie between May 20, 2025 and August 18, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against James Hardie Industries plc ("James Hardie" or the "Company") (NYSE: JHX) and reminds investors of the December 23, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
SKYE DEADLINE: Faruqi & Faruqi Reminds Skye Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" or the "Company") (NASDAQ: SKYE) and reminds investors of the January 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
AVTR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Avantor
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Avantor To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Avantor between March 5, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Avantor, Inc. ("Avantor" or the "Company") (NYSE: AVTR) and reminds investors of the December 29, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
Palantir Crushes 63% Growth While UiPath Celebrates Its First Profit
UiPath (NYSE: PATH) and Palantir Technologies (Nasdaq: PLTR) both beat Q3 estimates, but the results reveal fundamentally different AI business models.
...keep reeding on 247wallst.com
BAX DEADLINE: Faruqi & Faruqi Reminds Baxter International Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - BAX
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Baxter between February 23, 2022 and Ocober 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. ("Baxter" or the "Company") (NYSE: BAX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
Here's How Many Shares of the SPDR Portfolio S&P 500 High Dividend ETF (SPYD) You'd Need for $500 in Yearly Dividends
Dividends are the passive income you receive from owning stocks or ETFs. SPYD tracks the top 80 high-dividend-yielding companies in the S&P 500.
...keep reeding on fool.com
LRN DEADLINE: Faruqi & Faruqi Reminds Stride Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 - LRN
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Stride To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Stride between October 22, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Stride, Inc. ("Stride" or the "Company") (NYSE: LRN) and reminds investors of the January 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
Costco Holds Steady While Walmart Bets Big on E-Commerce Transformation
Costco Wholesale Corporation (NASDAQ: COST) and Walmart Inc.
...keep reeding on 247wallst.com
Top Wall Street analysts favor these 3 stocks for their growth potential
TipRanks' ranking service highlights three stocks, including Credo Technology and Walmart.
...keep reeding on cnbc.com
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with PM359, the Company's investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease (CGD) in the New England Journal of Medicine (NEJM). The data will also be presented in a poster session at the 67th American Society of Hematology (ASH) Annual Meeting, December 6-9, 2025 in Orlando, Florida.
...keep reeding on globenewswire.com
3 Nuclear Energy Stocks to Buy Before 2026
Cameco is a top provider of uranium and nuclear infrastructure in North America. Centrus procures low-enriched uranium and has longer-term plans to produce high-assay, low-enriched uranium for advanced reactors.
...keep reeding on fool.com
OWL DEADLINE: Faruqi & Faruqi Reminds Blue Owl Capital Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 2, 2026 - OWL
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Blue Owl to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Blue Owl between February 6, 2025 and November 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Blue Owl Capital Inc. ("Blue Owl" or the "Company") (NYSE: OWL) and reminds investors of the February 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
...keep reeding on newsfilecorp.com
Victoria's Secret: The Reasons Why The Post-Earnings Rally Is Not Justified
Victoria's Secret & Co. remains a sell despite recent outperformance and post-earnings rally. VSCO's quarterly sales grew 9% and beat estimates, but growth is flattened by a weak prior-year comparison and inconsistent profitability. Balance sheet concerns include accounts receivable rising faster than revenue and recent shareholder dilution.
...keep reeding on seekingalpha.com
Grocers See Increasing Evidence That Consumers Are Feeling More Strain
Consumers are stretching their budgets by making smaller, more frequent purchases and buying fewer discretionary items.
...keep reeding on investopedia.com
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
- Combination of evorpacept plus rituximab and lenalidomide (R 2 ) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R 2 alone
...keep reeding on globenewswire.com
US Stormwater Management Market Size Worth USD 15.05 Billion by 2033 | SNS Insider
Austin, Dec. 07, 2025 (GLOBE NEWSWIRE) -- US Stormwater Management Market Size and Growth Insights: According to the SNS Insider,"The U. S. Stormwater Management Market Size was USD 8. 25 billion in 2025E and is projected to grow at a CAGR of 7.
...keep reeding on globenewswire.com
BST: Technology Options CEF With 7.3% Yield, Growth, No Leverage, But Volatility
BlackRock Science and Technology Trust offers a 7.36% yield and trades at a -7.3% discount to NAV, focusing on high-growth tech equities. BST's buy-write strategy overwrites only 15–30% of the portfolio, enabling greater upside capture during bull markets compared to peers. The fund uses zero leverage and has a very strong long-term record, making it suitable for income-focused investors seeking high total returns. However, investors should be mindful of high volatility and generally much higher drawdowns compared to the broader market.
...keep reeding on seekingalpha.com
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT). Results were shared from the combined analysis of four-year data from the la.
...keep reeding on businesswire.com
Oil-Dri Corporation of America: Upside Hasn't Dried Up Yet
Oil-Dri Corporation of America remains a 'buy' despite near-term headwinds and recent underperformance versus the S&P 500. ODC's revenue grew 10.1% year-over-year, driven by strong business-to-business segment performance and strategic investments in high-value products. Management warns of a challenging first half for fiscal 2026 due to cost pressures and asset replacement expenses, but maintains a net cash position of $10.6 million.
...keep reeding on seekingalpha.com
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Media Release COPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R 2 ) resulted in statistically significant and clinically meaningful reduction in the risk of disease progression or death and overall response compared to R 2 alone EPKINLY + R 2 was recently approved by the U.S. Food and Drug Administration as the first and only bispecific-based therapy for follicular lymphoma in the second-line setting Results of EPCORE FL-1 simultaneously published in The Lancet Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE ® FL-1 study evaluating fixed duration EPKINLY ® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R 2 ) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study showed that treatment with EPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21, 95% CI: 0.14-0.31, p
...keep reeding on globenewswire.com
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE® FL-1 study evaluating fixed duration EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study showed that treatment with EPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21, 95% CI: 0.14-0.31, p
...keep reeding on businesswire.com
Longest 0% Intro APR Credit Cards This Week, Dec. 7, 2025: Interest-Free Breathing Room for up to 2 Years
This week's best 0% intro APR cards offer up to 24 months interest-free -- ideal for large purchases or tackling debt without extra costs.
...keep reeding on fool.com
Had $25K in a Wells Fargo Savings Account for 5 Years? You Just Lost $5,000 in Interest
Keeping money in a big-bank savings account costs you thousands over time, even with small balances.
...keep reeding on fool.com
The Venture X Just Dropped a 100K Bonus -- Here's Why It's a Big Deal
The Capital One Venture X is already one of the best travel cards out there -- now it's got a great welcome offer to match. Here's what to know.
...keep reeding on fool.com
Pay for Your Next Getaway: The Best Travel Cards Available This Week, Dec. 7, 2025
Don't wait until right before your next trip to apply for a new travel card. Here's why now's the best time to get an elite travel card for summer 2026 travel.
...keep reeding on fool.com
Here's What Happens When You Spend More Than $5,000 on Your Credit Card
Spending big on your credit card can trigger fraud checks, impact your score, and put you at risk of debt issues. Here's how to avoid these issues.
...keep reeding on fool.com
This High-Yield ETF Has Increased Payouts 13 Years Straight -- and It's Still Undervalued
The Schwab ETF focuses on quality, cash-flow strength, and consistent dividend payers. The fund has increased its total annual dividend every year since its 2011 inception.
...keep reeding on fool.com